clinically Proven Results
INTRAROSA is clinically proven to treat moderate to severe painful sex due to menopause.
Primary Efficacy Results
decrease in pain during sex
improvement in vaginal tissue*
These results are from two 12-week, randomized, double-blind, placebo-controlled studies that included 640 postmenopausal women with moderate to severe painful sex as their most bothersome symptom.
*Decreased percentage of parabasal cells, reduced vaginal pH, and increased percentage of superficial cells
Sustained decrease in pain during sex over
1 year of continued daily use at bedtime
These results are from a 52-week non-comparative, open-label clinical trial that included 183 postmenopausal women with moderate to severe painful sex as their most bothersome symptom.
Using INTRAROSA has worked to relieve my moderate to severe pain during sex.† I had no idea that my
vaginal tissue could be part of my problem.
– Linda W.
†In clinical trials, INTRAROSA was shown to reduce moderate to severe pain during sex
when used daily at bedtime for 12 weeks.
Individual results may vary.
Demonstrated Safety in INTRAROSA Clinical Trials
The most frequently reported side effects of INTRAROSA are vaginal discharge and changes on Pap smear
In a 52-week non-comparative clinical trial, the most frequently reported side effects were vaginal discharge (14% of women) and changes in Pap smear (2.1%)
INTRAROSA is the only prescription treatment for moderate to severe painful sex due to menopause with no boxed safety warning
Additional exploratory findings
In one clinical study, women completed a validated survey to understand their sexual function. These are initial findings that have not been intensely studied.§‖
INTRAROSA showed improvement in sexual function across all areas, including1§‖:
Pain with sexual activity
INTRAROSA is not indicated for the treatment of sexual dysfunction.
§Exploratory outcome measure.
‖Subjects were not diagnosed with sexual dysfunction.